Recent findings unveil the pharmacological modulation of imidazoline I 2 receptors (I 2-IR)
as a novel strategy to face unmet medical neurodegenerative diseases. In this work, we …

Imidazoline I2 receptors (I2-IR), widely distributed in the CNS and altered in patients that
suffer from neurodegenerative disorders, are orphans from a structural point of view, and …

The impact of neurodegenerative diseases (ND) is becoming unbearable for humankind
due to their vast prevalence and the lack of efficacious treatments. In this scenario, we …

Background and Purpose Activation of type 2 imidazoline receptors has been shown to
exhibit neuroprotective properties including anti‐apoptotic and anti‐inflammatory effects …

Background and Purpose The development of effective therapeutic strategies against
Alzheimer's disease (AD) remains a challenge. I2 imidazoline receptor ligands have a …

As populations increase their life expectancy, age-related neurodegenerative disorders
such as Alzheimer's disease have become more common. I 2-Imidazoline receptors (I 2-IR) …

Recent evidence suggests that I2-imidazoline ligands have neuroprotective properties in
animal models of neurodegeneration, such as Alzheimer's disease (AD). We recently …

Aggregation and neurotoxicity of amyloid β (Aβ) protein is a hallmark characteristic of
Alzheimer's disease (AD). In this study we compared the anti-aggregatory and …

The group of imidazoline-1 receptors (I1-IR) agonists encompasses drugs are currently used
in treatment of high blood pressure and hyperglycemia. The I1-IR protein structures have not …

The imidazoline I2 receptors (I2-IRs) are widely distributed in the brain, and I2-IR ligands
may have therapeutic potential as neuroprotective agents. Since structural data for I2-IR …